biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	3/26/2015 9:46:06 AM
	Read Replies (1) of 3661

IPH.PA -17% MARSEILLE, France, March 26, 2015 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB") completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol. In issuing this recommendation, the DSMB considers that treatment in the stopped arm cannot be superior to placebo. There is no concern with safety. Patients in the stopped arm will be followed up as planned. The trial remains blinded. The Company now expects that analysis on the primary efficacy endpoint, leukemia-free survival, will occur in Q2 2016.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next